Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (TAPAS)
Intravitreal Tissue Plasminogen Activator And Perfluoropropane for Neovascular Age-related Macular Degeneration With Associated Submacular Haemorrhage: a Multi-centre, Randomized, Double-masked, Sham-controlled, Factorial, Feasibility Study
Sponsor: King's College Hospital NHS Trust
This PHASE2/PHASE3 trial investigates Exudative Macular Degeneration and Retinal Hemorrhage and is currently completed. King's College Hospital NHS Trust leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jun 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Jun 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Unknown Status → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Unknown Status PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- King's College Hospital NHS Trust
For direct contact, visit the study record on ClinicalTrials.gov .